BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy"
BMO Capital Markets has upgraded Perspective Therapeutics (NYSEAMERICAN:CATX) to a "strong-buy" rating, while the broader analyst consensus remains "buy" with an average price target of $11.50. Despite mixed recent analyst actions and slightly below-forecast revenue, the company beat quarterly EPS expectations. Institutional investors own 54.66% of the stock, with several increasing their stakes.
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11
BMO Capital Markets has initiated coverage on Perspective Therapeutics Inc. (CATX.A) with an Outperform rating. The firm has also set a price target of $11 for the company's stock. This indicates a positive outlook from BMO regarding Perspective Therapeutics' future performance.
Perspective Therapeutics Market Sentiment
This article provides an overview of market sentiment for Perspective Therapeutics (CATX), including analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 17 analysts with an average price target of $11, a short interest of 24.6%, and details recent analyst actions with various ratings and price target revisions.
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital
BMO Capital has set a price target of $11.00 per share for Perspective Therapeutics (NYSEAMERICAN:CATX). This indicates a significant potential upside for the stock from its current trading levels. This news may be of interest to investors following the biotechnology and pharmaceutical sectors.
BMO Capital Initiates Perspective Therapeutics at Outperform
BMO Capital has initiated coverage on Perspective Therapeutics (CATX) with an "Outperform" rating. The company, a radiopharmaceutical developer, focuses on advanced cancer treatments using the alpha-emitting isotope 212Pb and imaging diagnostics. This initiation follows several recent developments for Perspective Therapeutics, including BofA Securities adjusting its price target and progress in its clinical trials for neuroendocrine tumors and meningioma.
BMO initiates Perspective Therapeutics stock at Outperform, $11 target
BMO Capital has initiated coverage on Perspective Therapeutics Inc. (NYSE:CATX) with an Outperform rating and an $11 price target, indicating significant upside potential. The company specializes in precision radioligand therapies, with its lead program, bamzireotide navoxetan, targeting neuroendocrine tumors. This positive outlook is supported by promising clinical data and recent analyst revisions, despite a slight adjustment in price target from Piper Sandler, and continued endorsement from BTIG.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received a "Moderate Buy" consensus recommendation from analysts, with eight buy ratings and one hold out of nine analysts. The average 12-month price target for the stock is $11.56, significantly higher than its recent trading price of $3.22. The company reported a quarterly loss of $0.22 per share, beating analyst estimates, and institutional investors own 54.66% of its stock.
BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6
BofA Securities has lowered its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $5, down from the previous target of $6. The firm has maintained its Buy rating on the company's stock.
Bank of America Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00
Bank of America has lowered its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $5.00 from $6.00, while maintaining a neutral rating, implying a potential upside of 56.99%. Despite this, analyst sentiment remains broadly positive with a "Moderate Buy" consensus and an average target price of $11.56. The company recently reported a narrower-than-expected quarterly loss but continues to post substantial losses as it develops early-stage cancer therapies.
BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6
BofA Securities has lowered its price target for Perspective Therapeutics (CATX) from $6 to $5, according to a report published on August 14, 2026. This adjustment comes as the radiopharmaceutical development company continues its work on advanced cancer treatments. The article also mentions recent news about Perspective Therapeutics, including data on its NET program and its neuroendocrine tumor therapy receiving EU Orphan Drug Designation.
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX
Dimensional Fund Advisors LP significantly increased its stake in Perspective Therapeutics, Inc. (CATX) by 391.6% in the first quarter, purchasing an additional 358,540 shares to hold a total of 450,097 shares valued at $1.88 million. Despite CATX stock recently trading down 4.9% at $3.10, institutional investors collectively own 54.66% of the company, and analysts maintain a consensus "Buy" rating with an average price target of $12.38. The company, which is advancing precision-targeted alpha therapies for cancer treatment, also reported a quarterly loss of $0.22 per share, outperforming estimates.
Perspective Therapeutics (CATX): Millennium group reports over 5% beneficial stake
Millennium Management LLC and affiliated entities have reported an amended beneficial ownership stake in Perspective Therapeutics (CATX). Integrated Core Strategies (US) LLC holds 5.2% of common stock, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 5.5% of the outstanding common stock. All reported shares indicate shared voting and dispositive power, with no sole voting or dispositive power claimed by any of the reporting persons.
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer
Oppenheimer analyst Jeff Jones reiterated a Buy rating on Perspective Therapeutics (CATX) with a $13.00 price target, based on his 5-star analyst track record. The company's Q1 earnings showed a revenue of $76 thousand and a GAAP net loss of $26.19 million. The analyst consensus for CATX is a Strong Buy with an average price target of $12.78.
Perspective Therapeutics: Q2 Earnings Snapshot
This article provides a brief "snapshot" of Perspective Therapeutics' Q2 earnings. No specific financial details or further information about the earnings are provided in the current content.
Piper Sandler cuts Perspective Therapeutics price target on timing
Piper Sandler has reduced its price target for Perspective Therapeutics (NYSE:CATX) to $14 from $16, while maintaining an Overweight rating, due to anticipated timing of clinical trial milestones. The company reaffirmed that pivotal site activation for bamzireotide navoxetan is expected around year-end 2026, and data for VMT01 are also expected in late 2026, while the next update for PSV359 has moved to 2027. Despite the price target adjustment, other analysts like RBC Capital and BTIG have reiterated positive ratings and price targets for Perspective Therapeutics, citing ongoing clinical developments and competitive advantages.
CATX Maintained by Piper Sandler -- Price Target Lowered to $14.
Piper Sandler has maintained an Overweight rating for Perspective Therapeutics Inc (CATX) but lowered its price target to $14.00 from $16.00, indicating a cautious outlook despite positive sentiment. CATX, operating in the radiopharmaceuticals sector, currently has a GF Score™ of 30/100, highlighting concerns regarding its profitability and growth, and appears overvalued based on its Price-to-Sales ratio. Guru and insider activity show mixed sentiment, with some increasing and others trimming positions.
Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Lowered to $14.00 at Piper Sandler
Piper Sandler has lowered its price target for Perspective Therapeutics (NYSEAMERICAN:CATX) to $14.00 from $16.00, while maintaining an "overweight" rating. This new target suggests a significant upside of 366.67% from the current stock price of $3.00. The company recently reported a narrower-than-expected quarterly loss of $0.22 per share, although revenue slightly missed estimates.
Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results
Perspective Therapeutics (NYSEAMERICAN:CATX) reported its quarterly earnings, beating analyst expectations with a loss of $0.22 per share against a consensus of $0.27, although revenue of $0.08 million was slightly below the $0.09 million estimate. The company's shares remained flat at $3.00, and institutional investors hold a significant portion of its stock. Analysts maintain a "Buy" rating with a consensus price target of $12.62 as the company progresses with its precision-targeted cancer therapies through clinical trials.
Perspective Therapeutics: Q2 Earnings Snapshot
This article provides a brief "snapshot" of Perspective Therapeutics' Q2 earnings. Due to the limited content, no detailed financial figures or specific performance indicators are available beyond the headline.
Perspective Therapeutics (NYSE: CATX) grows cash to $237M while advancing Phase 3-ready pipeline
Perspective Therapeutics announced its second-quarter 2026 results, reporting a significant increase in cash reserves to $237 million, up from $145 million at the end of 2025, which is expected to fund operations into late 2027. The company is progressing its lead candidate, VMT-α-NET, towards a Phase 3 study for neuroendocrine tumors with site activation anticipated around year-end 2026, subject to regulatory feedback. Despite an increased net loss of $26.8 million due to higher R&D expenses, the company continues to expand its radiopharmaceutical manufacturing network and advance other clinical programs.
Perspective Therapeutics Inc (CATX) Stock News Today
This page provides current stock news for Perspective Therapeutics Inc (CATX), a company in the Biotechnology & Medical Research sector. It displays the latest stock price, market cap, and indicates that more news will be added soon. The article primarily serves as a placeholder for updates on CATX.
State Street Corporation (NYSE: CATX) reports 6.05M-share, 5.3% stake in Perspective
State Street Corporation has reported a beneficial ownership of 6,051,771 shares, or 5.3%, of Perspective Therapeutics Inc. common stock, as detailed in a recent SCHEDULE 13G SEC filing. This filing indicates a passive investment, with State Street exercising shared voting power over 5,942,306 shares and shared dispositive power over all 6,051,771 shares. The ownership includes involvement from subsidiaries like SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, all classified as investment advisers.
Perspective Therapeutics, Inc. (CATX) stock price, news, quote and history
This article provides comprehensive financial information for Perspective Therapeutics, Inc. (CATX), including its current stock price, historical data, and analyst ratings. It details the company's focus on developing precision targeted alpha therapies for cancer, highlighting its drug candidates and clinical trials. The report also includes performance metrics, earnings trends, and a comparison with similar companies in the medical devices sector.
Perspective Therapeutics (CATX) Gets a Buy from Wedbush
Wedbush maintained a Buy rating on Perspective Therapeutics (CATX) with an $11.00 price target. The analyst consensus is a Strong Buy with an average price target of $13.33. The company reported a quarterly revenue of $76 thousand and a GAAP net loss of $26.19 million for the quarter ending March 31.
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Perspective Therapeutics (CATX) is outperforming the Medical sector this year, with a 9.5% year-to-date return compared to the sector's 0.4% loss. The company holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook. Another strong performer in the sector is Bristol Myers Squibb (BMY), which is up 21.4% year-to-date.
Perspective Therapeutics updates corporate presentation, highlights progress across 212Pb radiopharmaceutical portfolio
Perspective Therapeutics recently updated its corporate presentation, detailing advancements in its 212Pb-based radiopharmaceutical programs. Key highlights include an emphasis on regional isotope production, direct-to-hospital delivery, and progress in ongoing Phase 1/2a trials for various cancer treatments. The company's presentation also highlighted data from ASCO 2026, showing promising results for VMT-α-NET, and stressed the advantages of 212Pb for potent activity and combination therapies.
Perspective Therapeutics (NYSE: CATX) details 212Pb radiopharma pipeline
Perspective Therapeutics (NYSE: CATX) has updated its corporate presentation, outlining its strategy to redefine oncology treatment using next-generation radiopharmaceuticals built around the alpha-emitting isotope 212Pb. The company highlights its direct-to-hospital delivery model supported by integrated isotope production and regional manufacturing. Key programs, all in Phase 1/2a studies, include VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for advanced solid tumors.
CATX (Perspective Therapeutics) EBITDA Margin % : 0.00% (As of Mar. 2026)
This article from GuruFocus reports that Perspective Therapeutics (CATX) has an EBITDA Margin % of 0.00% as of March 2026. The company's EBITDA for the three months ending in March 2026 was -$24.96 million, with revenue at $0.00 million, leading to the 0.00% margin. GuruFocus assigns CATX a GF Score of 31/100 and notes two warning signs for investors to review.
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP
Avidity Partners Management LP significantly increased its stake in Perspective Therapeutics, Inc. (CATX) by 88.4% in the first quarter, making it their fourth largest holding. This move is part of a broader trend of institutional investors raising their positions in the company, with total institutional ownership reaching 54.66%. Despite minimal revenue and ongoing losses, analysts maintain a "Buy" rating for CATX with a consensus price target of $12.62, significantly above its current trading price.
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Perspective Therapeutics, Inc. announced it will release its second-quarter 2026 financial results and provide a business update on Monday, August 10, 2026, after market close. The company, a radiopharmaceutical developer, is focused on advanced treatments for various cancers using proprietary 212Pb technology and a theranostic approach. It is advancing clinical-stage programs for neuroendocrine tumors, melanoma, and solid tumors.
Perspective Therapeutics, Inc. Revenue Breakdown – AMEX:CATX
Perspective Therapeutics, Inc. (AMEX: CATX) generated $884,000 USD in revenue last year, primarily from its "Precision Targeted Alpha Therapies" segment. This figure is a decrease from $1.45 million USD the previous year, with the United States being the sole contributor to both years' revenues.
Perspective Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 10
Perspective Therapeutics, Inc. (CATX) will announce its second quarter 2026 financial results and provide a business update on August 10, 2026, after market close. The company, which specializes in radiopharmaceutical treatments for cancer using the alpha-emitting isotope 212Pb, is advancing clinical programs and expanding its supply network. The announcement will be available on the company's newsroom section, and while there are potential positives like a theranostic approach and pipeline advancement, the company also highlights risks related to clinical development costs, timelines, and regulatory hurdles.
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026, after the market closes. The company, a radiopharmaceutical developer, is focused on advanced treatments for various cancers using proprietary alpha-generating isotope technology. Its pipeline includes clinical-stage programs for neuroendocrine tumors, melanoma, and solid tumors, supported by its 224Ra/212Pb generator platform.
Perspective Therapeutics Inc (CATX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Perspective Therapeutics Inc (CATX), noting its current valuation score of 7.54, which ranks 161 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -2.08, while stating that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced it will report its second-quarter 2026 financial results and provide a business update on Monday, August 10, 2026, after market close. The company, a radiopharmaceutical development firm, is focused on advanced treatments for various cancers using its proprietary alpha-generating isotope 212Pb and theranostic approach. It is currently advancing several clinical-stage programs in the U.S.
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Perspective Therapeutics Inc (CATX), detailing its current score of 2.89 within the Biotechnology & Medical Research industry and its beta value of 1.74. The assessment includes data on volatility, maximum drawdown, return metrics, Sharpe Ratio, skewness, and liquidity. It highlights the stock's tendency for higher returns in up-markets but also larger declines in down-markets due to its beta.
BlackRock (CATX holder) discloses 6.8% beneficial stake in Perspective Therapeutics
BlackRock, Inc. has reported a 6.8% beneficial ownership stake in Perspective Therapeutics Inc. (CATX), holding 7,776,940 common shares as of June 30, 2026. The investment firm maintains sole voting power over 7,679,840 shares and sole dispositive power over all 7,776,940 shares. This disclosure, made via a SCHEDULE 13G filing, indicates a passive investment, with no single underlying client holding more than five percent of Perspective Therapeutics' outstanding common shares.
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Perspective Therapeutics (CATX) has experienced a recent bearish trend, but technical analysis suggests a potential reversal. The formation of a hammer chart pattern, combined with rising optimism from Wall Street analysts regarding future earnings, indicates that the stock could find support soon. Additionally, an upward trend in earnings estimate revisions and a Zacks Rank #2 (Buy) further strengthen the bullish outlook for CATX.
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Perspective Therapeutics Inc. (CATX), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The current price momentum score is 4.89, ranking 151st in its industry, with the stock trading between a resistance of $3.54 and a support of $2.45. While technical indicators show mixed signals, moving averages predominantly suggest a "Sell" signal for the stock based on current data.
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Perspective Therapeutics (CATX) has shown a bearish trend recently, but a hammer chart pattern suggests a potential trend reversal. This technical indicator, combined with rising optimism among Wall Street analysts and a Zacks Rank #2 (Buy), indicates that the stock could find support soon. The consensus EPS estimate for the current year has also increased, further enhancing the prospects of price appreciation.
Perspective Therapeutics (CATX) Stock Price, News & Analysis
This article provides a comprehensive overview of Perspective Therapeutics (CATX) stock, including its current price, market data, analyst ratings, and company overview. It highlights the company's focus on developing precision-targeted alpha therapies for oncology and includes recent news such as its Q2 2026 financial results report and European Orphan Medicinal Product Designation for [²¹²Pb]VMT-α-NET. The stock is currently rated as a "Buy" by analysts, with significant upside potential.
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
Perspective Therapeutics has been granted European orphan medicinal product designation for its radiopharmaceutical, [212Pb]VMT-α-NET, for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This designation offers development and commercial incentives, recognizing the drug's potential significant benefit for patients with limited treatment options. The company is evaluating [212Pb]VMT-α-NET in an ongoing Phase 1/2a study, with interim clinical data supporting its promise.
Perspective Therapeutics (CATX) Gains Orphan Drug Designation, Faces Valuation Challenges
Perspective Therapeutics (CATX) recently received orphan drug designation from the European Commission for its radiopharmaceutical candidate (Pb)VMT-alpha-NET, aimed at gastroenteropancreatic neuroendocrine tumors. Despite this regulatory milestone and a strong balance sheet, the early-stage biotech firm faces significant valuation challenges, reflected in its low GF Score of 31/100, zero current revenue, and unprofitability. Investors are weighing the promising technology and regulatory progress against inherent developmental risks and skepticism about near-term commercial viability.
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [²¹²Pb]VMT-α-NET in GEP-NETs
Perspective Therapeutics announced that its radiopharmaceutical, [²¹²Pb]VMT-α-NET, has received European orphan medicinal product designation for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This designation offers development and commercial incentives, including potential market exclusivity, and supports the drug's advancement in Europe. Interim clinical data from an ongoing Phase 1/2a study indicate promising benefits compared to existing therapies for SSTR2-positive tumors.
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for ...
Perspective Therapeutics announced that its radiopharmaceutical [²¹²Pb]VMT-α-NET has received Orphan Medicinal Product designation from the European Commission for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This designation offers development and commercial incentives, recognizing the significant benefit this therapy could provide to patients in Europe. [²¹²Pb]VMT-α-NET is currently in an ongoing Phase 1/2a study, with interim clinical data supporting its potential effectiveness compared to existing treatments.
Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation
Perspective Therapeutics announced that its neuroendocrine tumor therapy has received Orphan Drug Designation from the European Union. This designation supports the development of therapies for rare diseases, potentially offering incentives for the company. The therapy is currently in Phase I/IIa imaging and therapy trials.
CATX|Perspective Therapeutics Inc|Price:2.820|Chg%:-0.090
Perspective Therapeutics Inc. (CATX) is a radiopharmaceutical development company focused on advanced cancer treatments using its proprietary alpha-emitting isotope 212Pb technology. The company's stock is currently priced at $2.820, down 3.09%, and analysts have a "Buy" rating with a target price of $12.786, suggesting a significant upside. Despite strong institutional ownership and growth potential, the stock has shown weak performance over the past month and is trading sideways.
Perspective Therapeutics Market Sentiment
This article provides an overview of market sentiment for Perspective Therapeutics (CATX), including analyst consensus, short interest, options flow, and insider activity. Analysts show a "Buy" consensus with an average price target of $11, while short interest is high at 23.8%. Insider activity data for the last 30 days is not available, but the article references recent insider buying by Avi Kapoor among other articles about insider activity in various penny stocks.
CATX|Perspective Therapeutics Inc|Price:2.910|Chg%:-0.045
Perspective Therapeutics Inc. (CATX) is a radiopharmaceutical development company focused on treating cancers with an alpha-emitting isotope 212Pb. The company is advancing its melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs into Phase I/IIa clinical trials. This detailed overview includes the company profile, leadership, key financial data, and institutional shareholding information.
Spruce Street Capital LP Takes Position in Perspective Therapeutics, Inc. $CATX
Spruce Street Capital LP has taken a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), acquiring 2.63 million shares valued at approximately $10.96 million. This investment makes CATX the fund's 15th-largest holding. Despite the new institutional interest, the stock is trading below its 12-month high and moving averages, although it recently beat earnings expectations.
